Minulet (Ethinylestradiol, Gestodene)

Ethinylestradiol, a synthetic estrogen, suppresses the hypothalamic‑pituitary‑ovarian axis, leading to reduced secretion of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). This inhibition prevents the mid‑cycle surge that triggers ovulation, contributing to effective contraception.

The dosing regimen for Minulet is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet following the specific cycle outlined in the product’s prescribing information, but the exact schedule should be confirmed with a qualified prescriber.

Minulet is intended for use only when pregnancy is not desired. It should not be started during an existing pregnancy. While limited data exist for breastfeeding, most guidelines advise caution and recommend consulting a healthcare provider before using combined oral contraceptives while nursing.

To place an order, submit an enquiry on the Minulet product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minulet contains ethinylestradiol and gestodene, a third‑generation progestogen associated with a lower incidence of androgenic side effects such as acne. Compared with older formulations that use levonorgestrel, Minulet may offer improved cycle control and a more favourable lipid profile, though individual response can vary.

Minulet tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Minulet is taken orally, usually once daily at the same time each day. The tablets are swallowed with water and should be started on the first day of the menstrual period or as directed by a healthcare professional.

The most serious risks include venous and arterial thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Additional rare but severe concerns are severe hypertension, liver tumors, and allergic reactions that may require immediate medical attention.

Minulet is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, and in smokers over 35 years of age. It should also be avoided during pregnancy and in individuals with known hypersensitivity to any component of the product.